Related Experiment Video
Updated: Mar 21, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.9K
CYP1A2-163C/A (rs762551) polymorphism and bladder cancer risk: a case-control study
Y L Song1,2, L Wang2, J C Ren1
1Department of Urology, Qilu Hospital, Shandong University, Jinan, China.
Genetics and Molecular Research : GMR
|May 14, 2016
Summary
The CYP1A2-163C/A gene variant is linked to a higher risk of bladder cancer in Chinese individuals. This genetic polymorphism, specifically the -163A allele, shows a significant association with increased bladder cancer susceptibility.
Area of Science:
- Genetics
- Oncology
- Molecular Epidemiology
Background:
- The cytochrome P450 1A2 (CYP1A2) enzyme plays a role in metabolizing environmental carcinogens.
- Genetic variations in CYP1A2, such as the -163C/A polymorphism, may influence individual susceptibility to cancer.
- The association between CYP1A2-163C/A polymorphism and bladder cancer risk has not been previously studied in the Chinese population.
Purpose of the Study:
- To investigate the association between the CYP1A2-163C/A polymorphism and the risk of developing bladder cancer.
- To determine if specific genotypes or alleles of CYP1A2-163C/A are more prevalent in Chinese bladder cancer patients compared to healthy controls.
Main Methods:
- Genomic DNA was extracted from peripheral white blood cells of bladder cancer patients and healthy controls.
- CYP1A2 alleles were identified using polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP).
- Genotype and allele frequencies were compared using chi-square tests, and odds ratios (OR) with 95% confidence intervals (CI) were calculated using logistic regression models.
Main Results:
- The -163A allele was found significantly more frequently in bladder cancer patients (44.10%) than in controls (22.25%) (P < 0.001).
- Genotype frequencies differed significantly between cases and controls (P < 0.001), with the AA genotype showing a 3.72-fold increased risk (OR = 3.72; 95%CI = 1.55-7.16; P = 0.02).
- -163A allele carriers had an elevated risk of bladder cancer (OR = 4.89, 95%CI = 2.78-10.87, P = 0.01) in a multivariate COX regression model.
Conclusions:
- The CYP1A2-163C/A polymorphism is associated with an increased susceptibility to bladder cancer in the Chinese population.
- The -163A allele and AA genotype may serve as genetic markers for bladder cancer risk in this demographic.
- Further research is warranted to elucidate the functional impact of this polymorphism on CYP1A2 activity and bladder carcinogenesis.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
105
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
105
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
106
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
114
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
114
01:05Single Nucleotide Polymorphisms-SNPs
19.7K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.7K
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
58
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
58